Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty products, and OTC pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetic, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, drops, and respiratory/MDI/DPI/nasal sprays. Its product pipeline includes ISB 2001, a BCMA x CD38 x CD3 trispecific engagement by antibodies based on the T cell receptor trispecific antibody, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 1442, a CD38 x CD47 bispecific engagement by antibodies based on the T cell receptor biparatopic bispecific antibody that is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma and acute myeloid leukemia; and GRC 65327, a Cbi-b inhibitor, which is in pre-clinical study for the indication of solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 1 clinical trial for the treatment of autoimmune diseases; and ISB 830, a telazorlimab OX40 antagonist antibody that is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.

Revenue projections:

Revenue projections for GLENMARK
Revenue projections for GLENMARK

GLENMARK's revenue projections show a decrease from last year, which tends to make investors more cautious. This could have a negative impact on the company's bottom line, as lower revenues typically suggest reduced profitability and growth potential, prompting concern among investors.

Financial Ratios:

currentRatio 0.000000
forwardPE 29.978666
debtToEquity 12.776000
earningsGrowth 0.158000
revenueGrowth 0.151000
grossMargins 0.707090
operatingMargins 0.183380
trailingEps 37.780000
forwardEps 80.056930

GLENMARK's Forward PE is within a good range, showing that the stock price compares well to its earnings. This suggests it isn't overpriced and leaves room for growth, making the stock appealing to investors looking for value and growth opportunities.
GLENMARK's low Debt-to-Equity ratio means the company is not highly leveraged. This suggests a sound financial position with minimal reliance on debt, reducing risk and ensuring greater financial flexibility, making it a more stable option for investors.
GLENMARK's positive earnings and revenue growth suggest that the company is poised for business expansion. This financial strength indicates that GLENMARK is expected to continue growing, with rising profits and sales contributing to its long-term success.
GLENMARK's forward EPS exceeding its trailing EPS means the company is expected to be more profitable this year than last. This suggests an upward trend in earnings, with forecasts indicating that GLENMARK's financial performance will improve in the current financial year.

Price projections:

Price projections for GLENMARK
Price projections for GLENMARK

GLENMARK's price projections have gradually increased over time, indicating that analysts are becoming more optimistic about the company's prospects. This suggests confidence in GLENMARK's ability to achieve future growth.

Recommendation changes over time:

Recommendations trend for GLENMARK
Recommendations trend for GLENMARK


Analysts are favoring GLENMARK with a buy bias, highlighting the stock's potential as a solid investment. This recommendation might drive more investors to consider GLENMARK as a secure and profitable option for their money, contributing to a broader positive sentiment in the market.